support that simplifies access
a copay program, e‑vouchers, and more
Amerithroid is covered by many commercial plans, with copay assistance for eligible patients. We also offer a direct-to-patient, cash-pay option for families who prefer the convenience of having medicine delivered directly to their home.*
supporting access and lower copays
two ways to save
copay savings support with Relay Health eVoucherRx
Available at more than 50,000 pharmacies nationwide, including Walgreens and Walmart
Works with their insurance to help reduce their costs even further
No printing or forms required—everything is handled electronically
Copay discount is applied automatically when they show up to fill their prescription
If their pharmacy does not participate, they can visit the Relay Health website to find one that does
If their pharmacy does not participate, they can visit the Relay Health website to find one that does
pharmacy not in the Relay Health network?

No activation required
Patient can bring a physical card from your office to the pharmacy
Used with their insurance, it can help lower their costs
Applies a discount even if they pay cash
* Commercially insured patients will not have their prescription processed through their insurance. Subject to terms, conditions, and eligibility restrictions.
pharmacy not in the Relay Health network?

No activation required
Patient can bring a physical card from your office to the pharmacy
Used with their insurance, it can help lower their costs
Applies a discount even if they pay cash
* Commercially insured patients will not have their prescription processed through their insurance. Subject to terms, conditions, and eligibility restrictions.
pharmacy not in the Relay Health network?

No activation required
Patient can bring a physical card from your office to the pharmacy
Used with their insurance, it can help lower their costs
Applies a discount even if they pay cash
* Commercially insured patients will not have their prescription processed through their insurance. Subject to terms, conditions, and eligibility restrictions.



Home delivery
Home delivery
†
Medications shipped directly to your patient

Automatic refills
Never miss a dose or run out

As little as $30** for a month's supply

No signature required
Hassle-free delivery
prescribing amerithroid
To help ensure your patients receive amerithroid as prescribed, write “dispense as written” (DAW 1) on the prescription.§
†Commercially insured patients will not have their prescription processed through their insurance.‡Patients enrolling in Oliva2You may not utilize insurance benefits, including any federal, state, or government-funded insurance program. In addition, patients enrolling in Oliva2You may not have payments applied to true out-of-pocket (TrOOP) costs.**Subject to the terms, conditions, and eligibility restrictions outlined below.§Dispense as written or equivalent language in your state. Pharmacy rules and local laws may vary.
“Thyroid treatment is rooted in quality, consistency, and giving patients trusted options to support their personal care. That is our mission and commitment.”
—Daniel Akeson, CEO
Oliva Therapeutics
TERMS, CONDITIONS, AND ELIGIBILITY CRITERIA
This card is not valid for prescriptions submitted for reimbursement to Medicare, Medicaid, Medigap, VA, DOD, or TriCare, or where prohibited by law; to other federal or state programs (including any state pharmaceutical assistance programs); or to private indemnity or HMO insurance plans that reimburse you for the entire cost of your prescription drugs. Patients may not use this card if Amerithroid is covered under their Medicare prescription drug plan or if they are Medicare-eligible and enrolled in an employer-sponsored health plan or prescription drug benefit program for retirees.
This card is good for use only with an Amerithroid prescription at the time the prescription is filled by the pharmacist and dispensed to the patient.
This offer is good for 18 uses per patient, per calendar year, or until the program expires, whichever comes first.
Maximum reimbursement limits apply; patient out-of-pocket expenses may vary.
Oliva reserves the right to rescind, revoke, or amend this offer without notice.
Offer good only in the US, except California and Massachusetts, at participating retail pharmacies.
Void if prohibited by law, taxed, or restricted.
The selling, purchasing, trading, or counterfeiting of this card is prohibited by law.
By downloading the savings card, I certify that I am not covered by:
Any federal or state healthcare program, such as Medicare, Medicaid, etc., including state medical or pharmaceutical assistance programs;
The Medicare Prescription Drug Program (Part D), or in the coverage gap; or
Insurance that is paying the entire cost of the prescription
I agree to this certification and have read and accepted the Program Terms, Conditions, and Eligibility Criteria.
I certify that I am 18 years of age or older and completing this for myself or a dependent.









Note that DTE products, including amerithroid, have not been reviewed by the FDA for safety or efficacy.
Indications and Usage
Thyroid Tablets, USP are indicated for:
Replacement or supplemental therapy in hypothyroidism of any etiology (except transient hypothyroidism during recovery from subacute thyroiditis)
TSH suppression in the management of certain goiters and in thyroid cancer
contraindications
Uncorrected adrenal cortical insufficiency
Untreated thyrotoxicosis
Known hypersensitivity to thyroid hormone preparations or excipients
IMPORTANT RISK INFORMATION
BOXED WARNING
WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS
THYROID HORMONES, ALONE OR IN COMBINATION, SHOULD NOT BE USED FOR WEIGHT LOSS OR OBESITY TREATMENT.
IN EUTHYROID PATIENTS, DOSES WITHIN NORMAL HORMONAL REQUIREMENTS ARE INEFFECTIVE FOR WEIGHT REDUCTION.
LARGER DOSES MAY PRODUCE SERIOUS OR LIFE‑THREATENING TOXICITY, PARTICULARLY WHEN USED WITH SYMPATHOMIMETIC AMINES.
Warnings and Precautions
Cardiovascular Risk
Use with extreme caution in:
Patients with coronary artery disease or angina
Elderly patients
Therapy should be initiated at low doses and titrated carefully, as thyroid hormones may precipitate:
Angina
Arrhythmias
Myocardial infarction
Risk of Over‑Replacement (Hyperthyroidism)
Excess dosing may result in symptoms of hyperthyroidism, including:
Palpitations
Tachycardia
Nervousness
Heat intolerance
Liothyronine (T3) content may produce more rapid and pronounced effects
Endocrine Effects
May worsen:
Diabetes mellitus (increased insulin/oral hypoglycemic requirements)
Adrenal insufficiency (must be corrected prior to therapy)
Requires careful monitoring and dose adjustment
Anticoagulant Sensitivity
Thyroid hormones may increase response to oral anticoagulants
Monitor prothrombin time/INR and adjust anticoagulant dose as needed
Special Populations
Pediatric patients: Excess dosing may cause craniosynostosis
Pregnancy: Continue therapy; dose adjustments may be required
Lactation: Use with caution
Adverse Reactions
Adverse reactions are generally due to overdosage and resemble hyperthyroidism:
Palpitations
Tachycardia
Arrhythmias
Nervousness
Insomnia
Tremor
Heat intolerance
Other reactions are rare when properly dosed
Drug Interactions
Decreased absorption:
Cholestyramine (separate dosing by 4–5 hours)
Increased anticoagulant effects
Altered glycemic control with insulin or oral hypoglycemics
Estrogens/oral contraceptives:
May increase thyroid hormone requirements
Dosage and Administration
Dosage must be individualized based on clinical response and laboratory monitoring (TSH, T4, T3)
Typically initiated at low doses and titrated gradually, especially in patients with cardiovascular disease
Administer orally; consistency in administration is important
This is the most important safety information you should know about AMERITHROID®. For more information see full Prescribing Information, including BOXED WARNING.
To report SUSPECTED ADVERSE REACTIONS, contact Oliva Therapeutics, LLC at 1-877-200-6088, or FDA at 1-800-FDA-1088 or www.fda.gov/MedWatch.
All patient and physician images are representative only.
Note that DTE products, including amerithroid, have not been reviewed by the FDA for safety or efficacy.
Indications and Usage
Thyroid Tablets, USP are indicated for:
Replacement or supplemental therapy in hypothyroidism of any etiology (except transient hypothyroidism during recovery from subacute thyroiditis)
TSH suppression in the management of certain goiters and in thyroid cancer
contraindications
Uncorrected adrenal cortical insufficiency
Untreated thyrotoxicosis
Known hypersensitivity to thyroid hormone preparations or excipients
IMPORTANT RISK INFORMATION
BOXED WARNING
WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS
THYROID HORMONES, ALONE OR IN COMBINATION, SHOULD NOT BE USED FOR WEIGHT LOSS OR OBESITY TREATMENT.
IN EUTHYROID PATIENTS, DOSES WITHIN NORMAL HORMONAL REQUIREMENTS ARE INEFFECTIVE FOR WEIGHT REDUCTION.
LARGER DOSES MAY PRODUCE SERIOUS OR LIFE‑THREATENING TOXICITY, PARTICULARLY WHEN USED WITH SYMPATHOMIMETIC AMINES.
Warnings and Precautions
Cardiovascular Risk
Use with extreme caution in:
Patients with coronary artery disease or angina
Elderly patients
Therapy should be initiated at low doses and titrated carefully, as thyroid hormones may precipitate:
Angina
Arrhythmias
Myocardial infarction
Risk of Over‑Replacement (Hyperthyroidism)
Excess dosing may result in symptoms of hyperthyroidism, including:
Palpitations
Tachycardia
Nervousness
Heat intolerance
Liothyronine (T3) content may produce more rapid and pronounced effects
Endocrine Effects
May worsen:
Diabetes mellitus (increased insulin/oral hypoglycemic requirements)
Adrenal insufficiency (must be corrected prior to therapy)
Requires careful monitoring and dose adjustment
Anticoagulant Sensitivity
Thyroid hormones may increase response to oral anticoagulants
Monitor prothrombin time/INR and adjust anticoagulant dose as needed
Special Populations
Pediatric patients: Excess dosing may cause craniosynostosis
Pregnancy: Continue therapy; dose adjustments may be required
Lactation: Use with caution
Adverse Reactions
Adverse reactions are generally due to overdosage and resemble hyperthyroidism:
Palpitations
Tachycardia
Arrhythmias
Nervousness
Insomnia
Tremor
Heat intolerance
Other reactions are rare when properly dosed
Drug Interactions
Decreased absorption:
Cholestyramine (separate dosing by 4–5 hours)
Increased anticoagulant effects
Altered glycemic control with insulin or oral hypoglycemics
Estrogens/oral contraceptives:
May increase thyroid hormone requirements
Dosage and Administration
Dosage must be individualized based on clinical response and laboratory monitoring (TSH, T4, T3)
Typically initiated at low doses and titrated gradually, especially in patients with cardiovascular disease
Administer orally; consistency in administration is important
This is the most important safety information you should know about AMERITHROID®. For more information see full Prescribing Information, including BOXED WARNING.
To report SUSPECTED ADVERSE REACTIONS, contact Oliva Therapeutics, LLC at 1-877-200-6088, or FDA at 1-800-FDA-1088 or www.fda.gov/MedWatch.
All patient and physician images are representative only.
Note that DTE products, including amerithroid, have not been reviewed by the FDA for safety or efficacy.
Indications and Usage
Thyroid Tablets, USP are indicated for:
Replacement or supplemental therapy in hypothyroidism of any etiology (except transient hypothyroidism during recovery from subacute thyroiditis)
TSH suppression in the management of certain goiters and in thyroid cancer
contraindications
Uncorrected adrenal cortical insufficiency
Untreated thyrotoxicosis
Known hypersensitivity to thyroid hormone preparations or excipients
IMPORTANT RISK INFORMATION
BOXED WARNING
WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS
THYROID HORMONES, ALONE OR IN COMBINATION, SHOULD NOT BE USED FOR WEIGHT LOSS OR OBESITY TREATMENT.
IN EUTHYROID PATIENTS, DOSES WITHIN NORMAL HORMONAL REQUIREMENTS ARE INEFFECTIVE FOR WEIGHT REDUCTION.
LARGER DOSES MAY PRODUCE SERIOUS OR LIFE‑THREATENING TOXICITY, PARTICULARLY WHEN USED WITH SYMPATHOMIMETIC AMINES.
Warnings and Precautions
Cardiovascular Risk
Use with extreme caution in:
Patients with coronary artery disease or angina
Elderly patients
Therapy should be initiated at low doses and titrated carefully, as thyroid hormones may precipitate:
Angina
Arrhythmias
Myocardial infarction
Risk of Over‑Replacement (Hyperthyroidism)
Excess dosing may result in symptoms of hyperthyroidism, including:
Palpitations
Tachycardia
Nervousness
Heat intolerance
Liothyronine (T3) content may produce more rapid and pronounced effects
Endocrine Effects
May worsen:
Diabetes mellitus (increased insulin/oral hypoglycemic requirements)
Adrenal insufficiency (must be corrected prior to therapy)
Requires careful monitoring and dose adjustment
Anticoagulant Sensitivity
Thyroid hormones may increase response to oral anticoagulants
Monitor prothrombin time/INR and adjust anticoagulant dose as needed
Special Populations
Pediatric patients: Excess dosing may cause craniosynostosis
Pregnancy: Continue therapy; dose adjustments may be required
Lactation: Use with caution
Adverse Reactions
Adverse reactions are generally due to overdosage and resemble hyperthyroidism:
Palpitations
Tachycardia
Arrhythmias
Nervousness
Insomnia
Tremor
Heat intolerance
Other reactions are rare when properly dosed
Drug Interactions
Decreased absorption:
Cholestyramine (separate dosing by 4–5 hours)
Increased anticoagulant effects
Altered glycemic control with insulin or oral hypoglycemics
Estrogens/oral contraceptives:
May increase thyroid hormone requirements
Dosage and Administration
Dosage must be individualized based on clinical response and laboratory monitoring (TSH, T4, T3)
Typically initiated at low doses and titrated gradually, especially in patients with cardiovascular disease
Administer orally; consistency in administration is important
This is the most important safety information you should know about AMERITHROID®. For more information see full Prescribing Information, including BOXED WARNING.
To report SUSPECTED ADVERSE REACTIONS, contact Oliva Therapeutics, LLC at 1-877-200-6088, or FDA at 1-800-FDA-1088 or www.fda.gov/MedWatch.
All patient and physician images are representative only.
Amerithroid is a registered trademark of Oliva Therapeutics and is manufactured by Jerome Stevens Pharmaceuticals, Inc.
© 2026 Oliva Therapeutics. All rights reserved. US-AME-26009-10/26
This site is intended for U.S. healthcare professionals only.
Amerithroid is a registered trademark of Oliva Therapeutics and is manufactured by Jerome Stevens Pharmaceuticals, Inc.
© 2026 Oliva Therapeutics. All rights reserved. US-AME-26009-10/26
This site is intended for U.S. healthcare professionals only.
Amerithroid is a registered trademark of Oliva Therapeutics and is manufactured by Jerome Stevens Pharmaceuticals, Inc.
© 2026 Oliva Therapeutics. All rights reserved. US-AME-26009-10/26
This site is intended for U.S. healthcare professionals only.
Note that DTE products, including amerithroid, have not been reviewed by the FDA for safety or efficacy.
Indications and Usage
Thyroid Tablets, USP are indicated for:
Replacement or supplemental therapy in hypothyroidism of any etiology (except transient hypothyroidism during recovery from subacute thyroiditis)
TSH suppression in the management of certain goiters and in thyroid cancer
IMPORTANT RISK INFORMATION (CONT’D)
contraindications
Uncorrected adrenal cortical insufficiency
Untreated thyrotoxicosis
Known hypersensitivity to thyroid hormone preparations or excipients
IMPORTANT RISK INFORMATION
BOXED WARNING
WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS
THYROID HORMONES, ALONE OR IN COMBINATION, SHOULD NOT BE USED FOR WEIGHT LOSS OR OBESITY TREATMENT.
IN EUTHYROID PATIENTS, DOSES WITHIN NORMAL HORMONAL REQUIREMENTS ARE INEFFECTIVE FOR WEIGHT REDUCTION.
LARGER DOSES MAY PRODUCE SERIOUS OR LIFE‑THREATENING TOXICITY, PARTICULARLY WHEN USED WITH SYMPATHOMIMETIC AMINES.
Warnings and Precautions
Cardiovascular Risk
Use with extreme caution in:
Patients with coronary artery disease or angina
Elderly patients
Therapy should be initiated at low doses and titrated carefully, as thyroid hormones may precipitate:
Angina
Arrhythmias
Myocardial infarction
Risk of Over‑Replacement (Hyperthyroidism)
Excess dosing may result in symptoms of hyperthyroidism, including:
Palpitations
Tachycardia
Nervousness
Heat intolerance
Liothyronine (T3) content may produce more rapid and pronounced effects
Endocrine Effects
May worsen:
Diabetes mellitus (increased insulin/oral hypoglycemic requirements)
Adrenal insufficiency (must be corrected prior to therapy)
Requires careful monitoring and dose adjustment
Anticoagulant Sensitivity
Thyroid hormones may increase response to oral anticoagulants
Monitor prothrombin time/INR and adjust anticoagulant dose as needed
Special Populations
Pediatric patients: Excess dosing may cause craniosynostosis
Pregnancy: Continue therapy; dose adjustments may be required
Lactation: Use with caution
Adverse Reactions
Adverse reactions are generally due to overdosage and resemble hyperthyroidism:
Palpitations
Tachycardia
Arrhythmias
Nervousness
Insomnia
Tremor
Heat intolerance
Other reactions are rare when properly dosed
Drug Interactions
Decreased absorption:
Cholestyramine (separate dosing by 4–5 hours)
Increased anticoagulant effects
Altered glycemic control with insulin or oral hypoglycemics
Estrogens/oral contraceptives:
May increase thyroid hormone requirements
Dosage and Administration
Dosage must be individualized based on clinical response and laboratory monitoring (TSH, T4, T3)
Typically initiated at low doses and titrated gradually, especially in patients with cardiovascular disease
Administer orally; consistency in administration is important
This is the most important safety information you should know about AMERITHROID®. For more information see full Prescribing Information, including BOXED WARNING.
To report SUSPECTED ADVERSE REACTIONS, contact Oliva Therapeutics, LLC at 1-877-200-6088, or FDA at 1-800-FDA-1088 or www.fda.gov/MedWatch.
All patient and physician images are representative only.

Note that DTE products, including amerithroid, have not been reviewed by the FDA for safety or efficacy.
Indications and Usage
Thyroid Tablets, USP are indicated for:
Replacement or supplemental therapy in hypothyroidism of any etiology (except transient hypothyroidism during recovery from subacute thyroiditis)
TSH suppression in the management of certain goiters and in thyroid cancer
IMPORTANT RISK INFORMATION (CONT’D)
contraindications
Uncorrected adrenal cortical insufficiency
Untreated thyrotoxicosis
Known hypersensitivity to thyroid hormone preparations or excipients
IMPORTANT RISK INFORMATION
BOXED WARNING
WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS
THYROID HORMONES, ALONE OR IN COMBINATION, SHOULD NOT BE USED FOR WEIGHT LOSS OR OBESITY TREATMENT.
IN EUTHYROID PATIENTS, DOSES WITHIN NORMAL HORMONAL REQUIREMENTS ARE INEFFECTIVE FOR WEIGHT REDUCTION.
LARGER DOSES MAY PRODUCE SERIOUS OR LIFE‑THREATENING TOXICITY, PARTICULARLY WHEN USED WITH SYMPATHOMIMETIC AMINES.
Warnings and Precautions
Cardiovascular Risk
Use with extreme caution in:
Patients with coronary artery disease or angina
Elderly patients
Therapy should be initiated at low doses and titrated carefully, as thyroid hormones may precipitate:
Angina
Arrhythmias
Myocardial infarction
Risk of Over‑Replacement (Hyperthyroidism)
Excess dosing may result in symptoms of hyperthyroidism, including:
Palpitations
Tachycardia
Nervousness
Heat intolerance
Liothyronine (T3) content may produce more rapid and pronounced effects
Endocrine Effects
May worsen:
Diabetes mellitus (increased insulin/oral hypoglycemic requirements)
Adrenal insufficiency (must be corrected prior to therapy)
Requires careful monitoring and dose adjustment
Anticoagulant Sensitivity
Thyroid hormones may increase response to oral anticoagulants
Monitor prothrombin time/INR and adjust anticoagulant dose as needed
Special Populations
Pediatric patients: Excess dosing may cause craniosynostosis
Pregnancy: Continue therapy; dose adjustments may be required
Lactation: Use with caution
Adverse Reactions
Adverse reactions are generally due to overdosage and resemble hyperthyroidism:
Palpitations
Tachycardia
Arrhythmias
Nervousness
Insomnia
Tremor
Heat intolerance
Other reactions are rare when properly dosed
Drug Interactions
Decreased absorption:
Cholestyramine (separate dosing by 4–5 hours)
Increased anticoagulant effects
Altered glycemic control with insulin or oral hypoglycemics
Estrogens/oral contraceptives:
May increase thyroid hormone requirements
Dosage and Administration
Dosage must be individualized based on clinical response and laboratory monitoring (TSH, T4, T3)
Typically initiated at low doses and titrated gradually, especially in patients with cardiovascular disease
Administer orally; consistency in administration is important
This is the most important safety information you should know about AMERITHROID®. For more information see full Prescribing Information, including BOXED WARNING.
To report SUSPECTED ADVERSE REACTIONS, contact Oliva Therapeutics, LLC at 1-877-200-6088, or FDA at 1-800-FDA-1088 or www.fda.gov/MedWatch.
All patient and physician images are representative only.

Note that DTE products, including amerithroid, have not been reviewed by the FDA for safety or efficacy.
Indications and Usage
Thyroid Tablets, USP are indicated for:
Replacement or supplemental therapy in hypothyroidism of any etiology (except transient hypothyroidism during recovery from subacute thyroiditis)
TSH suppression in the management of certain goiters and in thyroid cancer
IMPORTANT RISK INFORMATION (CONT’D)
contraindications
Uncorrected adrenal cortical insufficiency
Untreated thyrotoxicosis
Known hypersensitivity to thyroid hormone preparations or excipients
IMPORTANT RISK INFORMATION
BOXED WARNING
WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS
THYROID HORMONES, ALONE OR IN COMBINATION, SHOULD NOT BE USED FOR WEIGHT LOSS OR OBESITY TREATMENT.
IN EUTHYROID PATIENTS, DOSES WITHIN NORMAL HORMONAL REQUIREMENTS ARE INEFFECTIVE FOR WEIGHT REDUCTION.
LARGER DOSES MAY PRODUCE SERIOUS OR LIFE‑THREATENING TOXICITY, PARTICULARLY WHEN USED WITH SYMPATHOMIMETIC AMINES.
Warnings and Precautions
Cardiovascular Risk
Use with extreme caution in:
Patients with coronary artery disease or angina
Elderly patients
Therapy should be initiated at low doses and titrated carefully, as thyroid hormones may precipitate:
Angina
Arrhythmias
Myocardial infarction
Risk of Over‑Replacement (Hyperthyroidism)
Excess dosing may result in symptoms of hyperthyroidism, including:
Palpitations
Tachycardia
Nervousness
Heat intolerance
Liothyronine (T3) content may produce more rapid and pronounced effects
Endocrine Effects
May worsen:
Diabetes mellitus (increased insulin/oral hypoglycemic requirements)
Adrenal insufficiency (must be corrected prior to therapy)
Requires careful monitoring and dose adjustment
Anticoagulant Sensitivity
Thyroid hormones may increase response to oral anticoagulants
Monitor prothrombin time/INR and adjust anticoagulant dose as needed
Special Populations
Pediatric patients: Excess dosing may cause craniosynostosis
Pregnancy: Continue therapy; dose adjustments may be required
Lactation: Use with caution
Adverse Reactions
Adverse reactions are generally due to overdosage and resemble hyperthyroidism:
Palpitations
Tachycardia
Arrhythmias
Nervousness
Insomnia
Tremor
Heat intolerance
Other reactions are rare when properly dosed
Drug Interactions
Decreased absorption:
Cholestyramine (separate dosing by 4–5 hours)
Increased anticoagulant effects
Altered glycemic control with insulin or oral hypoglycemics
Estrogens/oral contraceptives:
May increase thyroid hormone requirements
Dosage and Administration
Dosage must be individualized based on clinical response and laboratory monitoring (TSH, T4, T3)
Typically initiated at low doses and titrated gradually, especially in patients with cardiovascular disease
Administer orally; consistency in administration is important
This is the most important safety information you should know about AMERITHROID®. For more information see full Prescribing Information, including BOXED WARNING.
To report SUSPECTED ADVERSE REACTIONS, contact Oliva Therapeutics, LLC at 1-877-200-6088, or FDA at 1-800-FDA-1088 or www.fda.gov/MedWatch.
All patient and physician images are representative only.




